1.
Herz
; 45(7): 652-658, 2020 Nov.
Artículo
en Inglés
| MEDLINE
| ID: mdl-32564097
RESUMEN
Deep vein thrombosis and pulmonary artery embolism are common and serious concomitant diseases in patients with cancer. The prophylaxis and therapy of such venous thromboembolic events (VTE) in oncology have so far been achieved with low-molecular-weight heparins. An increasing number of studies show evidence of the use of direct oral anticoagulants. However, since none of the possible options were shown to have a clear advantage in all patients, the individual decision to use a drug should be made depending on its effectiveness in preventing VTE, the risk of bleeding, the nature of the cancer, the interactions with other medications, the route of administration, and finally the cost of treatment.
Asunto(s)
Neoplasias , Embolia Pulmonar , Tromboembolia Venosa , Trombosis de la Vena , Anticoagulantes/uso terapéutico , Heparina de Bajo-Peso-Molecular/uso terapéutico , Humanos , Neoplasias/complicaciones , Tromboembolia Venosa/diagnóstico , Tromboembolia Venosa/tratamiento farmacológico , Tromboembolia Venosa/etiología
2.
Med Teach
; 39(11): 1202, 2017 11.
Artículo
en Inglés
| MEDLINE
| ID: mdl-28826309